NEW YORK (GenomeWeb News) — Oxford Expression Technologies and Eden Biodesign have struck a co-marketing agreement to serve pharmaceutical researchers involved in protein expression.
Under the agreement, OET will offer access to Eden Biodesign's process development, clinical trial current good manufacturing practice services. Eden Biodesign's customers, in turn, will be able to use OET's range of baculovirus capabilities for their individual protein expression requirements. In particular, Eden's customers will have access to OET's experience in troubleshooting baculovirus expression and the use of its flashback technology for increasing protein yield in difficult to express proteins.
OET was founded in 2007 by a collaboration between Oxford Brookes University and the Natural Environment Research Council to provide custom proteins for research purposes.
Eden Biodesign is focused on guiding clients through process development, manufacturing, regulatory and technology transfer challenges.